Addex's repeated ATM draws signal ongoing capital needs with no near-term revenue catalyst; the 33% dilution and going-concern overhang should pressure the already-depressed stock. Watch for further ATM sales or a larger dilutive offering—at $5M market cap, the company likely needs additional capital before year-end 2027.
Price Chart
Executive Summary
Addex Therapeutics raised $2.8 million gross proceeds via an ATM equity offering with H.C. Wainwright, selling 437,869 ADSs representing 52.5 million shares. The cash runway extends to Q4 2027, but the company faces persistent going-concern risk given its prior FY2025 cash burn of CHF 6.8M and only $1.6M in cash as of year-end 2025. This dilutive raise provides near-term survival capital at the cost of substantial shareholder dilution.
Key Facts
- Gross proceeds of USD 2.8 million (CHF 2.2 million) raised through ATM offering
- 437,869 ADSs sold, representing 52,544,280 underlying shares
- Outstanding shares increased to 210,292,217 (ex-treasury)
- Cash runway extended to Q4 2027
- Prior FY2025 20-F reported CHF 6.8M net loss, CHF 1.6M cash, going concern emphasis
- FY2025 revenue declined to CHF 0.03M from CHF 0.4M year-over-year
- Material weakness in internal controls persists per prior 20-F
- Market cap approximately $5M, analyst consensus 0% bullish (5 Sell, 2 Strong Sell)
Financial Impact
Raised $2.8M which extends runway ~3-4 quarters; shares outstanding increased by approximately 33.3% from 157.7M to 210.3M (ex-treasury), meaning significant dilution for existing holders. At current cash burn rate (~CHF 6.8M/year), $2.8M covers roughly 5-6 months of operations.
Risk Factors
- Going-concern risk remains high despite extended runway—cash still insufficient for full clinical development
- Additional dilution from further ATM draws or follow-on offerings likely
- Zero analyst bullish ratings; market skepticism already priced in
- No near-term revenue; Indivior partnership ended; pipeline all preclinical/early-stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005744 |
| Document: 0001171843-26-005744-index-headers.html | 0001171843-26-005744 |
| Document: 0001171843-26-005744-index.html | 0001171843-26-005744 |
| Document: 0001171843-26-005744.txt | 0001171843-26-005744 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.18 | awaiting T+60 | — | $2.99 (−5.97%) |
Oct 2, 2026 25d ago | 6-K | $3.07 | awaiting T+60 | — | $2.99 (−2.61%) |
Sep 28, 2026 29d ago | 6-K | $2.81 | awaiting T+60 | — | $2.99 (−6.41%) |
Sep 25, 2026 4w ago | 6-K | $3.65 | awaiting T+60 | — | $2.99 (−18.08%) |
Aug 26, 2026 8w ago | 6-K | $4.23 | awaiting T+60 | — | $2.99 (+29.31%) |
Jul 8, 2026 15w ago | 6-K | $5.89 $2.98 | ▼ −49.41% | ▼ −51.90% | $2.99 (−49.24%) |
Jun 30, 2026 17w ago | 6-K | $5.70 $3.45 | ▲ +39.47% | ▲ +42.29% | $2.99 (+47.54%) |
Jun 25, 2026 17w ago | 6-K | $5.94 $3.40 | ▲ +42.76% | ▲ +46.49% | $2.99 (+49.66%) |
May 15, 2026 23w ago | 20-F | $6.83 $5.95 | ▲ +12.88% | ▲ +17.74% | $2.99 (+56.22%) |
Apr 23, 2026 26w ago | 6-K | $6.14 $5.60 | ▼ −8.79% | ▼ −13.81% | $2.99 (−51.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers